Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-60. (Canceled)

61. (Currently amended) A method of inhibiting fusion ~~infection~~ of a CCR5+, CD4+ human cell ~~by~~ with a macrophage-tropic HIV-1, which comprises contacting the CCR5+, CD4+ cell with a non-chemokine agent which is a CCR5 chemokine receptor antagonist which

(a) binds to ~~a~~ the CCR5 chemokine receptor on the surface of the CCR5+, CD4+ cell;

(b) competes with RANTES, MIP-1α and MIP-1β for binding to the CCR5 chemokine receptor on the surface of the CCR5+, CD4+ cell;

(c) inhibits binding of $HIV1_{JR-FL}$ gp120 to the CCR5+, CD4+ cell;

~~(b)~~ (d) ~~blocks~~ inhibits fusion of $HIV\text{-}1_{JR-FL}$ with a PM-1 cell;

~~(c)~~ (e) does not ~~block~~ inhibit fusion of $HIV\text{-}1_{BRU}$ with ~~such~~ a PM-1 cell; and

~~(d)~~ (f) does not activate an inflammatory response upon binding to the CCR5 chemokine receptor on the surface of the CCR5+, CD4+ cell;

in an amount and under conditions such that fusion of the macrophage-tropic HIV-1 ~~to~~ with the CCR5+, CD4+ cell is inhibited. ~~, so as to thereby inhibit infection of the CD4+ cell by the macrophage tropic HIV-1~~.

62-65. (Canceled)

66. (Previously presented) The method of claim 61, wherein the CCR5 chemokine receptor antagonist is a polypeptide.

67. (New) The method of claim 61, wherein the CCR5 chemokine receptor antagonist is a non-chemokine peptide obtained by adding amino acids to, or deleting amino acids from, the N-terminus of a chemokine selected from the group consisting of RANTES, MIP-1α

and MIP-1β.

68. (New) The method of claim 61, wherein the CCR5 chemokine receptor antagonist is an antibody or a portion of an antibody.

69. (New) The method of claim 68, wherein the CCR5 chemokine receptor antagonist is a monoclonal antibody or a portion of a monoclonal antibody.

70. (New) The method of claim 68, wherein the CCR5 chemokine receptor antagonist is a polyclonal antibody.